Introduction

Published: June 10, 2009
Abstract Views: 136
PDF: 102
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Certain immunomodulatory drugs are establishing a role in the treatment of several haematological malignancies, including myelodysplastic syndromes (MDS), multiple myeloma (MM), and chronic lymphocytic leukaemia (CLL). The use of these drugs, together with recent advances in our understanding of the underlying molecular pathways that affect the course of disease, is changing the way we approach the management of patients with haematological malignancies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Dimopoulos, M. (2009). Introduction. Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.507